Long-term results of rituximab–intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy-Reference-Cited by-同舟云学术

Long-term results of rituximab–intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy

Published:2016-05-10 Issue:1 Volume:28 Page:50-54
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Oktem Ayse¹,Akay Bengu Nisa²,Boyvat Ayse²,Kundakci Nihal²,Erdem Cengizhan²,Bostancı Seher²,Sanli Hatice²,Kocyigit Pelin²

Affiliation:

1. Department of Dermatology, Ankara Numune Training and Research Hospital, Ankara, Turkey;

2. Department of Dermatology, Faculty of Medicine, Ankara University, Ankara, Turkey

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2016.1179711

Reference41 articles.

1. Epidermolysis Bullosa Acquisita

2. Epidermolysis bullosa acquisita: What’s new?

3. Epidermolysis bullosa acquisita

4. Clinical Presentation, Pathogenesis, Diagnosis, and Treatment of Epidermolysis Bullosa Acquisita

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunobullous Diseases;Rook's Textbook of Dermatology;2024-03-19

2. A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy;Experimental Dermatology;2023-05-07

3. Treatment of Recurrent Epidermolysis Bullosa Acquisita With Tofacitinib;JAMA Dermatology;2023-03-01

4. Epidermolysis Bullosa Acquisita—Current and Emerging Treatments;Journal of Clinical Medicine;2023-02-01

5. Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin;American Journal of Clinical Dermatology;2023-01-11